JP6239628B2 - がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ - Google Patents

がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ Download PDF

Info

Publication number
JP6239628B2
JP6239628B2 JP2015534826A JP2015534826A JP6239628B2 JP 6239628 B2 JP6239628 B2 JP 6239628B2 JP 2015534826 A JP2015534826 A JP 2015534826A JP 2015534826 A JP2015534826 A JP 2015534826A JP 6239628 B2 JP6239628 B2 JP 6239628B2
Authority
JP
Japan
Prior art keywords
antibody
seq
variable region
chain variable
kir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015534826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532292A (ja
JP2015532292A5 (OSRAM
Inventor
ロバート エフ． グラツィアーノ，
ロバート エフ． グラツィアーノ，
アショク ケー． グプタ，
アショク ケー． グプタ，
ス ヨン キム，
ス ヨン キム，
ジョン ウィギントン，
ジョン ウィギントン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2015532292A publication Critical patent/JP2015532292A/ja
Publication of JP2015532292A5 publication Critical patent/JP2015532292A5/ja
Application granted granted Critical
Publication of JP6239628B2 publication Critical patent/JP6239628B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015534826A 2012-10-02 2013-10-02 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ Expired - Fee Related JP6239628B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708784P 2012-10-02 2012-10-02
US61/708,784 2012-10-02
PCT/US2013/063068 WO2014055648A1 (en) 2012-10-02 2013-10-02 Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017211743A Division JP6533270B2 (ja) 2012-10-02 2017-11-01 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ

Publications (3)

Publication Number Publication Date
JP2015532292A JP2015532292A (ja) 2015-11-09
JP2015532292A5 JP2015532292A5 (OSRAM) 2016-11-24
JP6239628B2 true JP6239628B2 (ja) 2017-11-29

Family

ID=49326890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015534826A Expired - Fee Related JP6239628B2 (ja) 2012-10-02 2013-10-02 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ
JP2017211743A Expired - Fee Related JP6533270B2 (ja) 2012-10-02 2017-11-01 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ
JP2019096727A Expired - Fee Related JP6707697B2 (ja) 2012-10-02 2019-05-23 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017211743A Expired - Fee Related JP6533270B2 (ja) 2012-10-02 2017-11-01 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ
JP2019096727A Expired - Fee Related JP6707697B2 (ja) 2012-10-02 2019-05-23 がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ

Country Status (27)

Country Link
US (2) US20150290316A1 (OSRAM)
EP (2) EP3263601B1 (OSRAM)
JP (3) JP6239628B2 (OSRAM)
KR (1) KR102130865B1 (OSRAM)
CN (1) CN104837868B (OSRAM)
AU (1) AU2013327116C1 (OSRAM)
BR (1) BR112015007184A2 (OSRAM)
CA (1) CA2887027C (OSRAM)
CY (1) CY1119799T1 (OSRAM)
DK (1) DK2904011T3 (OSRAM)
EA (1) EA038920B1 (OSRAM)
ES (1) ES2643887T3 (OSRAM)
HK (1) HK1210786A1 (OSRAM)
HR (1) HRP20171788T1 (OSRAM)
HU (1) HUE035503T2 (OSRAM)
IL (1) IL237960B (OSRAM)
LT (1) LT2904011T (OSRAM)
MX (2) MX367042B (OSRAM)
NO (1) NO2787245T3 (OSRAM)
NZ (1) NZ631405A (OSRAM)
PL (1) PL2904011T3 (OSRAM)
PT (1) PT2904011T (OSRAM)
RS (1) RS56624B1 (OSRAM)
SG (2) SG10201702421TA (OSRAM)
SI (1) SI2904011T1 (OSRAM)
SM (1) SMT201700540T1 (OSRAM)
WO (1) WO2014055648A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018058849A (ja) * 2012-10-02 2018-04-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101853702B1 (ko) 2009-12-07 2018-05-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 항-종양 항체 치료를 향상시키는 방법
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015198311A1 (en) * 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and kir for cancer therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
KR102357893B1 (ko) * 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
KR20170060042A (ko) * 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
ES2772307T3 (es) * 2014-10-28 2020-07-07 Childrens Univ Hospital Tuebingen Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
CN105669862A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗人pd-l1/kir双特异性抗体及其制备方法和应用
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
KR20250004095A (ko) 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
KR20170138555A (ko) 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
KR20190080992A (ko) 2015-05-21 2019-07-08 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
SMT202100131T1 (it) 2015-07-14 2021-05-07 Bristol Myers Squibb Co Metodo di trattamento di un cancro usando un inibitore di checkpoint immunitari; anticorpo che si lega al recettore della morte programmata-1 (pd-1) o al ligando della morte programmata 1 (pd-l1)
SG10202010506TA (en) 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
ES2839212T3 (es) 2015-09-29 2021-07-05 Inst Nat Sante Rech Med Métodos para determinar el estado metabólico de linfomas B
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
JP2019503349A (ja) * 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CA3007421A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
HRP20231156T1 (hr) 2015-12-22 2024-01-05 Regeneron Pharmaceuticals, Inc. Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
RS61901B1 (sr) * 2016-01-21 2021-06-30 Innate Pharma Neutralizacija inhibitornih puteva u limfocitima
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
DK3964529T3 (da) 2016-01-22 2025-06-30 MabQuest SA Ikke-blokerende pd1-specifikke antistoffer
KR20180101584A (ko) * 2016-01-27 2018-09-12 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료
CN107286242B (zh) 2016-04-01 2019-03-22 中山康方生物医药有限公司 抗pd-1的单克隆抗体
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
EA201892587A1 (ru) 2016-05-20 2019-04-30 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201900200XA (en) 2016-07-14 2019-02-27 Scholar Rock Inc Tgfb antibodies, methods, and uses
BR112018013653B1 (pt) * 2016-10-15 2020-12-15 Innovent Biologics (Suzhou) Co., Ltd Anticorpos anti-pd-1, processo para produção do mesmo e uso dos anticorpos
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
WO2018172508A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CA3058175A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7402691B2 (ja) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５抗体薬物複合体による併用療法
JP7257967B2 (ja) * 2017-05-01 2023-04-14 ザ チルドレンズ メディカル センター コーポレーション 抗ｐｄ１抗体試薬に関する方法および組成物
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CN118078987A (zh) * 2017-05-16 2024-05-28 伊缪诺金公司 抗folr1免疫缀合物与抗pd-1抗体的组合
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
ES3041991T3 (en) 2017-05-25 2025-11-17 Leidos Inc Pd-1 and ctla-4 dual inhibitor peptides
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
WO2019023624A1 (en) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
AU2018410849B2 (en) 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
EP3883964A1 (en) 2018-11-20 2021-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
IL282838B2 (en) 2018-12-21 2025-05-01 Valerio Therapeutics Conjugated nucleic acid molecules and their uses
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
US20220107323A1 (en) 2019-01-30 2022-04-07 Inserm(Institut National De La Santé Et De La Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
EP3924520A1 (en) 2019-02-13 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
EP3935085A1 (en) * 2019-03-06 2022-01-12 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
US20220220565A1 (en) 2019-04-30 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CA3141162A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7415385B2 (ja) * 2019-09-06 2024-01-17 株式会社リコー ヒータ制御装置、画像形成装置、ヒータの制御方法およびヒータの制御プログラム
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20220354811A1 (en) 2019-10-03 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
US20240301497A1 (en) 2019-10-17 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
US20240122938A1 (en) 2019-10-29 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4076508A1 (en) 2019-12-19 2022-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20230072528A1 (en) 2020-02-05 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
CA3189692A1 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
CA3198203A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
US20230416838A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4308118A1 (en) 2021-03-17 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating melanoma
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
JP2024536383A (ja) 2021-10-06 2024-10-04 ジェンマブ エー／エス 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20240426823A1 (en) 2021-11-03 2024-12-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
US20240294926A1 (en) 2021-12-16 2024-09-05 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP4452257A1 (en) 2021-12-21 2024-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
IL316628A (en) 2022-05-12 2024-12-01 Genmab As Binding agents capable of binding to CD27 in combination therapy
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
KR20250089513A (ko) 2022-10-19 2025-06-18 아스텔라스세이야쿠 가부시키가이샤 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용
EP4605000A1 (en) 2022-10-21 2025-08-27 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024163658A1 (en) * 2023-02-01 2024-08-08 Cephalon Llc Compositions and methods for anti-pacap igg4 antibodies
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
CN118671340B (zh) * 2024-07-12 2025-01-21 济南金域医学检验中心有限公司 检测nk大颗粒淋巴细胞的抗体组合、试剂盒及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA209001A (en) 1921-03-01 William K. Ketteringham, Jr. Fastener for trims and jambs
CA209003A (en) 1921-03-01 Krogman Joseph Whiffletree connector
US4971178A (en) 1989-02-02 1990-11-20 Inventio Ag Elevator system with independent limiting of a speed pattern in terminal zones
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
MXPA05013923A (es) 2003-07-02 2006-08-11 Univ Genova Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia.
LT1648507T (lt) 2003-07-24 2017-04-25 Innate Pharma S.A. Būdai ir kompozicijos, skirti terapinių antikūnų efektyvumo padidinimui, naudojant nk ląsteles stiprinančius junginius
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
PL1836225T3 (pl) 2005-01-06 2012-05-31 Novo Nordisk As Czynniki wiążące kir i sposoby ich stosowania
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US9447185B2 (en) 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
EP2109460B1 (en) * 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
JP6224457B2 (ja) 2010-11-22 2017-11-01 イネイト・ファルマ・ソシエテ・アノニム Ｎｋ細胞調節治療及び悪性血液疾患の治療方法
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
TWI560200B (en) 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
AU2013327116C1 (en) * 2012-10-02 2018-08-30 Bristol-Myers Squibb Company Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018058849A (ja) * 2012-10-02 2018-04-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ

Also Published As

Publication number Publication date
EP2904011A1 (en) 2015-08-12
EA038920B1 (ru) 2021-11-10
WO2014055648A1 (en) 2014-04-10
SG11201502496WA (en) 2015-04-29
EP3263601B1 (en) 2021-11-24
CY1119799T1 (el) 2018-06-27
PT2904011T (pt) 2017-10-27
MX2019004193A (es) 2019-08-05
SMT201700540T1 (it) 2018-01-11
IL237960A0 (en) 2015-05-31
HUE035503T2 (en) 2018-05-02
US20180099045A1 (en) 2018-04-12
JP2018058849A (ja) 2018-04-12
AU2013327116C1 (en) 2018-08-30
MX367042B (es) 2019-08-02
CA2887027A1 (en) 2014-04-10
RS56624B1 (sr) 2018-03-30
MX2015003985A (es) 2015-11-16
AU2013327116A1 (en) 2015-04-16
IL237960B (en) 2020-08-31
BR112015007184A2 (pt) 2017-08-08
JP2015532292A (ja) 2015-11-09
EP3263601A1 (en) 2018-01-03
ES2643887T3 (es) 2017-11-27
JP2019163299A (ja) 2019-09-26
CN104837868A (zh) 2015-08-12
CA2887027C (en) 2021-11-16
EA201590671A1 (ru) 2015-10-30
KR102130865B1 (ko) 2020-08-05
DK2904011T3 (en) 2017-12-04
NZ631405A (en) 2017-01-27
SG10201702421TA (en) 2017-05-30
NO2787245T3 (OSRAM) 2018-03-10
LT2904011T (lt) 2017-11-10
HRP20171788T1 (hr) 2017-12-29
CN104837868B (zh) 2022-04-29
SI2904011T1 (sl) 2017-10-30
US20150290316A1 (en) 2015-10-15
JP6533270B2 (ja) 2019-06-19
AU2013327116B2 (en) 2018-05-17
KR20150067227A (ko) 2015-06-17
PL2904011T3 (pl) 2018-01-31
JP6707697B2 (ja) 2020-06-10
HK1210786A1 (en) 2016-05-06
EP2904011B1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
JP6707697B2 (ja) がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ
JP7480248B2 (ja) 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ
US10688180B2 (en) Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US20240238416A1 (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms
CA2924524C (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EA048407B1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160930

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171101

R150 Certificate of patent or registration of utility model

Ref document number: 6239628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees